Gotham Asset Management LLC reduced its position in Doximity, Inc. (NASDAQ:DOCS - Free Report) by 11.7% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 47,989 shares of the company's stock after selling 6,372 shares during the quarter. Gotham Asset Management LLC's holdings in Doximity were worth $2,562,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors have also recently bought and sold shares of DOCS. FMR LLC increased its holdings in Doximity by 37.6% in the fourth quarter. FMR LLC now owns 9,409,313 shares of the company's stock valued at $502,363,000 after buying an additional 2,571,580 shares during the last quarter. Arrowstreet Capital Limited Partnership grew its holdings in shares of Doximity by 708.7% during the fourth quarter. Arrowstreet Capital Limited Partnership now owns 1,510,416 shares of the company's stock valued at $80,641,000 after purchasing an additional 1,323,634 shares during the last quarter. Invesco Ltd. raised its position in shares of Doximity by 525.1% during the 4th quarter. Invesco Ltd. now owns 1,272,403 shares of the company's stock worth $67,934,000 after purchasing an additional 1,068,849 shares during the period. Franklin Resources Inc. raised its position in shares of Doximity by 1,178.3% during the 4th quarter. Franklin Resources Inc. now owns 1,062,211 shares of the company's stock worth $56,711,000 after purchasing an additional 979,113 shares during the period. Finally, Fundsmith LLP acquired a new stake in shares of Doximity during the 4th quarter worth approximately $37,934,000. 87.19% of the stock is owned by institutional investors.
Analyst Upgrades and Downgrades
A number of analysts have recently weighed in on DOCS shares. KeyCorp dropped their price target on Doximity from $83.00 to $70.00 and set an "overweight" rating on the stock in a research report on Wednesday, April 16th. The Goldman Sachs Group increased their price objective on Doximity from $58.00 to $80.00 and gave the stock a "neutral" rating in a report on Monday, February 10th. Canaccord Genuity Group decreased their price target on Doximity from $71.00 to $50.00 and set a "hold" rating for the company in a research note on Friday. William Blair reaffirmed an "outperform" rating on shares of Doximity in a research note on Friday. Finally, Piper Sandler upgraded Doximity from a "neutral" rating to an "overweight" rating and increased their price objective for the company from $31.00 to $78.00 in a research report on Friday, February 7th. Eleven investment analysts have rated the stock with a hold rating, eight have given a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat, Doximity currently has a consensus rating of "Moderate Buy" and a consensus target price of $61.78.
Read Our Latest Research Report on DOCS
Insiders Place Their Bets
In other Doximity news, Director Kira Scherer Wampler sold 2,000 shares of the stock in a transaction on Thursday, May 1st. The shares were sold at an average price of $56.93, for a total transaction of $113,860.00. Following the transaction, the director now directly owns 16,618 shares of the company's stock, valued at $946,062.74. This represents a 10.74% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, CFO Anna Bryson sold 45,000 shares of the stock in a transaction on Thursday, May 1st. The stock was sold at an average price of $57.23, for a total transaction of $2,575,350.00. Following the transaction, the chief financial officer now directly owns 357,165 shares in the company, valued at $20,440,552.95. The trade was a 11.19% decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 37.40% of the company's stock.
Doximity Stock Performance
Shares of NASDAQ:DOCS traded up $1.29 during midday trading on Monday, hitting $53.85. 4,627,671 shares of the stock were exchanged, compared to its average volume of 2,084,370. Doximity, Inc. has a 52-week low of $25.00 and a 52-week high of $85.21. The business's fifty day simple moving average is $57.40 and its two-hundred day simple moving average is $57.95. The company has a market capitalization of $10.05 billion, a PE ratio of 53.85, a P/E/G ratio of 4.10 and a beta of 1.41.
Doximity (NASDAQ:DOCS - Get Free Report) last announced its quarterly earnings data on Thursday, May 15th. The company reported $0.38 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.27 by $0.11. Doximity had a return on equity of 21.75% and a net margin of 36.60%. During the same quarter last year, the business earned $0.25 earnings per share. The company's quarterly revenue was up 17.1% compared to the same quarter last year. As a group, equities analysts anticipate that Doximity, Inc. will post 0.99 EPS for the current year.
Doximity Profile
(
Free Report)
Doximity, Inc operates a cloud-based digital platform for medical professionals in the United States. The company's platform provides its members with tools built for medical professionals, enabling them to collaborate with their colleagues, coordinate patient care, conduct virtual patient visits, stay up to date with the latest medical news and research, and manage their careers.
Read More

Before you consider Doximity, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Doximity wasn't on the list.
While Doximity currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.